Fournier Pharma Has Been Granted Orphan Drug Designation By The European Commission (EC) For ANATIBANT For The Treatment Of Moderate And Severe Traumatic Brain Injury 
10/19/2005 5:10:39 PM

Fournier Pharma announced today that ANATIBANT has been granted orphan drug designation by the European Commission (EC) for the treatment of moderate and severe traumatic brain injury following the favorable opinion of the European Agency for the Evaluation of Medicinal Products (EMEA).